Table 2.

Association with pericardial disease

	HR for pericardial disease	Χ2	P value
Treatment with ICI	7.05 (3.73 to 13.35)	36.02	<0.001
Multivariate model
Treatment with ICI	4.37 (2.09 to 9.14)	15.41	<0.001
Lung cancer	5.46 (2.96 to 10.10)	29.35	<0.001
Prior radiation	0.75 (0.32 to 1.79)	0.42	0.52
Prior pericardial disease	2.56 (0.62 to 10.72)	1.67	0.20
History of cardiovascular events	0.15 (0.02 to 1.08)	3.56	0.06
Platinum-based therapy	1.17 (0.64 to 2.14)	0.27	0.60
Pre-ICI corticosteroid use	1.99 (0.97 to 4.09)	3.50	0.06

Risks of pericardial disease in the 2842 patients treated with ICI were compared with reference group including 2699 age-type and cancer-type matched patients with metastatic disease who did not receive ICI treatment (design 1).

ICI, immune checkpoint inhibitor.